The study data showed a 20% increased long-term risk for atrial fibrillation in patients with hospital-diagnosed moderate to severe atopic dermatitis.
Pfizer announced positive topline results from the phase 3 JADE MONO-2 trial of abrocitinib, an oral Janus kinase 1 inhibitor, for the treatment of moderate to severe atopic dermatitis.
This study supports the use of dupilumab as a systemic treatment for long-term management of moderate to severe AD without routine laboratory monitoring in clinical practice.
From the patient’s perspective, higher atopic dermatitis severity is associated with poorer HRQoL — a burden that may provide motivation for more effective management of atopic dermatitis.
Notable improvement with dupilumab in the treatment of moderate to severe atopic dermatitis was seen in all racial subgroups.
Study findings suggest that temperature, relative humidity, and air pollution are significantly associated with outpatient visits for atopic dermatitis.
Treatment varies greatly for pediatric patients with atopic dermatitis as drugs with known risks continue to be popular and beneficial agents are rarely prescribed.
The safety and efficacy profile from this study supports the role of dupilumab as continuous long-term treatment for patients with moderate to severe atopic dermatitis.
Cutaneous comorbidity is frequent in those with atopic dermatitis, suggesting the need for comprehensive, dermatologically guided diagnostics.
Dilute apple cider vinegar soaks had no significant effect on skin barrier integrity but did cause skin irritation in the majority of participants, this study finds.